Pre-RSNA Mammography Update

This year marks the 100th Annual Meeting of the Radiological Society of North America (RSNA). Held in Chicago every fall, RSNA is an exciting time where radiology vendors announce and showcase the latest innovations in medical imaging. As we prepare for this year’s meeting on November 30th, I thought it would be a good time to review changes that have occurred in the mammography market over that past few months.

GE Healthcare SenoClaireGE Announces FDA Approval

On September 3rd, GE Healthcare announced the FDA approval of their SenoClaire digital breast tomosynthesis solution. SenoClaire is an add-on to GE’s Senographe Essential and Senographe Care platforms. Some features that make this solution unique are its Step & Shoot tube motion and Adaptive Statistical Interactive Reconstruction (ASiRDBT). SenoClaire’s introduction adds competition to a market currently dominated by Hologic. It will be exciting to see the effect thiswill have on price and negotiation strategies for providers looking to invest in the digital breast tomosynthesis market.

Reimbursement Changes

Vendor options are not the only change happening in the world of breast tomosynthesis. The Centers for Medicare and Medicaid Services released reimbursement rates on October 31st for both screening and diagnostic breast tomosynthesis exams. These rates go into effect January 1, 2015. A detailed explanation is on the American College of Radiology’s website.

According to Peter J. Valenti III, President of Hologic’s Breast and Skeletal Health Solutions:

The availability of reimbursement for 3D mammography is yet another validation of the importance of this game-changing technology in the screening and detection of breast cancer.

Studies are proving time and time again the value provided through digital breast tomosynthesis imaging, especially for those women with dense breasts. I expect to see a major focus on the value of this technology at RSNA this year. As MD Buyline analysts are in attendance at RSNA this year, we will continue to keep up to date on any exciting advancements! For a more in-depth review, be sure to read our recent article published at ITN – The Evolution of 3-D Tomosynthesis.

Rachael Bennett, BHS, R.T.(R)(T)
Rachael Bennett, BHS, R.T.(R)(T), Clinical Analyst — Ms. Bennett joined MD Buyline in 2008 with seven years of clinical experience in the medical field. Ms. Bennett is the primary clinical analyst for linear accelerators, stereotactic radiosurgery, mammography systems, biopsy systems and other radiation oncology and women’s health capital equipment codes. She graduated from Baylor Allied Health School with a major in radiography and went on to specialize in radiation therapy at Washburn University. She currently holds registries as both a radiographer and radiation therapist through the American Registry of Radiologic Technologists (ARRT).